- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
OncoCyte is a diagnostics & research business based in the US. OncoCyte shares (OCX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.04 – a decrease of 2.56% over the previous week. OncoCyte employs 43 staff and has a trailing 12-month revenue of around $1 million.
Our top picks for where to buy OncoCyte stock
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy OncoCyte stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – OCX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy OncoCyte stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
OncoCyte stock price (NASDAQ: OCX)
Use our graph to track the performance of OCX stocks over time.OncoCyte shares at a glance
Information last updated 2024-10-25.
| Latest market close | $3.04 |
|---|---|
| 52-week range | $2.08 - $4.34 |
| 50-day moving average | $3.08 |
| 200-day moving average | $2.98 |
| Wall St. target price | $4.13 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-4.28 |
Is it a good time to buy OncoCyte stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
OncoCyte price performance over time
Historical closes compared with the close of $3.04 from 2024-10-25
| 1 week (2024-10-21) | -2.56% |
|---|---|
| 1 month (2024-09-27) | 5.56% |
| 3 months (2024-07-26) | -9.12% |
| 6 months (2024-04-26) | 22.58% |
| 1 year (2023-10-27) | 33.33% |
|---|---|
| 2 years (2022-10-28) | 340.58% |
| 3 years (2021-10-28) | 3.4 |
| 5 years (2019-10-28) | 93.63% |
OncoCyte financials
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $188,000 |
| Return on assets TTM | -16.67% |
| Return on equity TTM | -101.76% |
| Profit margin | 0% |
| Book value | $1.70 |
| Market Capitalization | $53 million |
TTM: trailing 12 months
OncoCyte share dividends
We're not expecting OncoCyte to pay a dividend over the next 12 months.
Have OncoCyte's shares ever split?
OncoCyte's shares were split on a 1:20 basis on 24 July 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your OncoCyte shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for OncoCyte shares which in turn could have impacted OncoCyte's share price.
OncoCyte share price volatility
Over the last 12 months, OncoCyte's shares have ranged in value from as little as $2.08 up to $4.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OncoCyte's is 1.006. This would suggest that OncoCyte's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
OncoCyte overview
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. .
Frequently asked questions
What percentage of OncoCyte is owned by insiders or institutions?Currently 14.112% of OncoCyte shares are held by insiders and 50.578% by institutions. How many people work for OncoCyte?
Latest data suggests 43 work at OncoCyte. When does the fiscal year end for OncoCyte?
OncoCyte's fiscal year ends in December. Where is OncoCyte based?
OncoCyte's address is: 15 Cushing, Irvine, CA, United States, 92618 What is OncoCyte's ISIN number?
OncoCyte's international securities identification number is: US68235C1071 What is OncoCyte's CUSIP number?
OncoCyte's Committee on Uniform Securities Identification Procedures number is: 68235C107
More resources on Finder
More guides on Finder
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
SoFi Invest vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
SoFi Invest® review 2024: Simple investing, free CFP access
SoFi Invest is a commission-free platform with both active and automated investment accounts.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
-
Robinhood Review 2024: IRA Match and No Commissions
A deep dive into the highlights and limitations of Robinhood.
Ask a question